Methylmalonic Acidemia with Homocystinuria: A Patient Guide
At a Glance
Methylmalonic acidemia with homocystinuria is a rare inherited disorder in which cells cannot process vitamin B12 properly, causing methylmalonic acid and homocysteine to build up. Lifelong B12 injections, often with betaine and specialist monitoring, help control the condition and reduce complications.
Methylmalonic Acidemia with Homocystinuria (MMA-HCU) is a rare genetic condition that fundamentally changes how the body uses Vitamin B12 (cobalamin). The most common form is the cblC defect (caused by biallelic MMACHC variants), though other disorders (such as cblD, cblF, cblJ, and cblX) can produce related findings.
In most people, Vitamin B12 is easily converted into the “keys” required to unlock vital chemical reactions within the cells. For those with this condition, the cells absorb B12 but the internal machinery needed to process it is broken. This creates a double-sided problem: the body cannot perform essential tasks, and two substances—methylmalonic acid (MMA) and homocysteine (tHcy)—begin to build up to toxic levels [1][2].
The condition typically presents in one of two distinct ways depending on when symptoms first appear. The early-onset form is often diagnosed in infancy, sometimes through newborn screening, and can cause challenges with growth, muscle tone, and early neurological development [3][4]. The late-onset form can appear at any point from childhood through adulthood. In these cases, the symptoms are often more subtle and varied, potentially involving sudden changes in mood or behavior, difficulty walking, or unexplained kidney and heart issues [5][6].
Because the problem lies deep within the cells, managing the condition requires a specialized approach. Standard oral vitamins or dietary changes are not enough because the primary problem is intracellular conversion of cobalamin after uptake. Instead, the standard of care is lifelong, high-dose hydroxocobalamin injections, which provide a reliable, high exposure under specialist supervision that improves residual intracellular processing [7][8]. This treatment is often paired with other supplements, such as betaine, to help clear the buildup of homocysteine and protect the organs from damage [9].
Living with MMA-HCU requires constant vigilance because it is a multisystem condition. The elevated levels of acids can impact the eyes, potentially leading to vision loss that requires monitoring by specialized eye doctors using tools like OCT (Optical Coherence Tomography) and ERG (Electroretinography) [10]. It can also affect the kidneys (TMA or HUS) and the blood pressure in the lungs (Pulmonary Hypertension), making regular check-ups with a full team of specialists a necessity [11][5]. Furthermore, common illnesses like a fever or a stomach bug can stress the body’s metabolism, potentially triggering an emergency that requires immediate medical intervention [12].
While the diagnosis is life-changing, it is also manageable. The goal of modern treatment is to stabilize the body’s internal chemistry and prevent long-term complications. With a dedicated care team and a consistent treatment routine, individuals with MMA-HCU can focus on growth, development, and living a full life beyond their diagnosis [13].
Disclaimer: This guide provides educational information. Your emergency letter and metabolic team’s specific instructions always take priority over any general thresholds or guidance found here.
In this guide
6 chapters
Understanding Your MMA-HCU Diagnosis
Learn what an MMA-HCU diagnosis means, how the cblC defect disrupts vitamin B12 processing, symptoms to watch for, and the lifelong treatments that help.
The Biology of B12: Why the cblC Defect Happens
Learn how the cblC defect disrupts B12 processing in methylmalonic acidemia with homocystinuria, causing high MMA and homocysteine and low methionine.
Recognizing Red Flags and Handling Emergencies
Learn which methylmalonic acidemia with homocystinuria symptoms require an ER visit, when to call 911, and how to use your emergency letter during illness.
The Standards of Care: Managing Your Chemistry
Learn MMA-HCU treatment for methylmalonic acidemia with homocystinuria, including hydroxocobalamin, betaine, and safe nutrition advice for long-term care.
Long-Term Health: Monitoring Your Eyes, Heart, and Brain
Learn how MMA-HCU can affect the eyes, kidneys, heart, and brain, and why ongoing vision, kidney, heart, and neurological monitoring matters over time.
Building Your Team and Long-Term Monitoring
Learn how methylmalonic acidemia with homocystinuria is monitored through coordinated care, adult transition, pregnancy planning, and family genetic counseling.
Common questions in this guide
What is methylmalonic acidemia with homocystinuria (MMA-HCU)?
Is MMA-HCU always caused by the cblC defect?
What treatment is used for MMA-HCU?
How do early- and late-onset MMA-HCU differ?
What complications should people with MMA-HCU be monitored for?
What should I do if I have a fever or stomach illness?
Can people with MMA-HCU live a full life?
Get notified when new evidence is published on Methylmalonic acidemia with homocystinuria.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (13)
- 1
The vitamin B12 processing enzyme, mmachc, is essential for zebrafish survival, growth and retinal morphology.
Sloan JL, Achilly NP, Arnold ML, et al.
Human molecular genetics 2020; (29(13)):2109-2123 doi:10.1093/hmg/ddaa044.
PMID: 32186706 - 2
Inherited defects of cobalamin metabolism.
Watkins D, Rosenblatt DS
Vitamins and hormones 2022; (119()):355-376 doi:10.1016/bs.vh.2022.01.010.
PMID: 35337626 - 3
[Kidney disease in cobalamin C deficiency].
Lemoine M, Grangé S, Guerrot D
Nephrologie & therapeutique 2019; (15(4)):201-214 doi:10.1016/j.nephro.2019.03.011.
PMID: 31130431 - 4
The Follow-Up of Chinese Patients in cblC Type Methylmalonic Acidemia Identified Through Expanded Newborn Screening.
Ling S, Wu S, Shuai R, et al.
Frontiers in genetics 2022; (13()):805599 doi:10.3389/fgene.2022.805599.
PMID: 35242167 - 5
Late-onset methylmalonic acidemia and homocysteinemia (cblC disease): systematic review.
Arhip L, Brox-Torrecilla N, Romero I, et al.
Orphanet journal of rare diseases 2024; (19(1)):20 doi:10.1186/s13023-024-03021-3.
PMID: 38245797 - 6
Late-onset cblC defect: clinical, biochemical and molecular analysis.
Ding S, Ling S, Liang L, et al.
Orphanet journal of rare diseases 2023; (18(1)):306 doi:10.1186/s13023-023-02890-4.
PMID: 37770946 - 7
Late-onset cobalamin C disease: rare but treatable.
Aliyar A, Endrakanti M, Singh RK, et al.
Practical neurology 2022; doi:10.1136/practneurol-2022-003447.
PMID: 35803728 - 8
Would, early, versus late hydroxocobalamin dose intensification treatment, prevent cognitive decline, macular degeneration and ocular disease, in 5 patients with early-onset cblC deficiency?
Scalais E, Geron C, Pierron C, et al.
Molecular genetics and metabolism 2023; (140(3)):107681 doi:10.1016/j.ymgme.2023.107681.
PMID: 37604084 - 9
Improved biochemical and neurodevelopmental profiles with high-dose hydroxocobalamin therapy in cobalamin C defect.
Olivieri G, Greco B, Cairoli S, et al.
Journal of inherited metabolic disease 2025; (48(1)):e12787 doi:10.1002/jimd.12787.
PMID: 39152755 - 10
Ocular disease in the cobalamin C defect: a review of the literature and a suggested framework for clinical surveillance.
Weisfeld-Adams JD, McCourt EA, Diaz GA, Oliver SC
Molecular genetics and metabolism 2015; (114(4)):537-46.
PMID: 25742969 - 11
Renal thrombotic microangiopathy in patients with cblC defect: review of an under-recognized entity.
Beck BB, van Spronsen F, Diepstra A, et al.
Pediatric nephrology (Berlin, Germany) 2017; (32(5)):733-741 doi:10.1007/s00467-016-3399-0.
PMID: 27289364 - 12
Newborn Screening for Methylmalonic Acidemia in a Chinese Population: Molecular Genetic Confirmation and Genotype Phenotype Correlations.
Zhou W, Li H, Wang C, et al.
Frontiers in genetics 2018; (9()):726 doi:10.3389/fgene.2018.00726.
PMID: 30728829 - 13
Prospective evaluation of pregnancy outcome in an Italian woman with late-onset combined homocystinuria and methylmalonic aciduria.
Grandone E, Martinelli P, Villani M, et al.
BMC pregnancy and childbirth 2019; (19(1)):318 doi:10.1186/s12884-019-2474-5.
PMID: 31470807
This guide about MMA-HCU is for informational purposes only and does not constitute medical advice. Follow your metabolic team’s individualized emergency and sick-day instructions, which take priority over general information here.